Implications for cancer genetics practice of pro-actively assessing family history in a General Practice cohort in North West London

Familial Cancer

Volumn 11, Issue 1, 2012, Pages 107-113

  Kohut, Kelly ^a   D'Mello, Lucia ^a   Bancroft, Elizabeth K ^b   Thomas, Sarah ^a   Young, Mary Anne ^a   Myhill, Kathryn ^a   Shanley, Susan ^a   Briggs, Brian H J ^c   Newman, Michelle ^c   Saraf, Ifthikhar M ^c   Cox, Penny ^c   Scambler, Sarah ^c   Wagman, Lyndon ^c   Wyndham, Michael T ^c   Eeles, Rosalind A ^a,b   Ferris, Michelle ^c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c Lane End Medical Group   (United Kingdom)

Author keywords

Ashkenazi; Ashkenazi Jewish; BRCA1; BRCA2; Cancer risk; Gene testing; General practice

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER INCIDENCE; FAMILY HISTORY; FEMALE; FOLLOW UP; GENE MUTATION; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; PATIENT COUNSELING; PRIORITY JOURNAL; QUESTIONNAIRE; TRANSLATIONAL RESEARCH; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; COHORT STUDIES; FEASIBILITY STUDIES; FEMALE; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; INCIDENCE; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PATIENT EDUCATION AS TOPIC; PATIENT SATISFACTION; PHYSICIAN'S PRACTICE PATTERNS; PILOT PROJECTS; PROGNOSIS; YOUNG ADULT;

EID: 84858228118     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-011-9482-6     Document Type: Article

References (12)

1. Antoniou AC, Pharoah PDP, Narod S et al (2005) Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet 42:602-603 (Pubitemid 40993838)
2. Antoniou AC, Cunningham AP, Peto J et al (2008) The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 98:1457-1466 (Pubitemid 351543573)
3. The Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. JNCI 9115:1310-1316
4. Domchek SM, Friebel TM, Neuhausen SL et al (2006) Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 7(3): 223-229 (Pubitemid 43286452)
5. Ferris M, Easton D, Doherty R et al (2007) A population-based audit of ethnicity and breast cancer risk in one General Practice catchment area in North London, UK: implications for practice. Hered Cancer Clin Pract 5(3):157-160 (Pubitemid 47573517)
6. Grann VR, Jacobson JS, Thomason D et al (2002) Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol 20:2520-2529 (Pubitemid 34525739)
7. Hartge P, Struewing JP, Wacholder S et al (1999) The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Human Genet 64:963-970 (Pubitemid 30463027)
8. Metcalfe KA, Poll A, Royer R et al (2010) Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol 28:387-391
9. Rubenstein WS, Jiang H, Dellafave L et al (2009) Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: a call for diaglogue. Genet Med 22:629-639
10. Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401-1408 (Pubitemid 27208598)
11. Thompson D, Easton DF (2001) Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Human Genet 68:410-419 (Pubitemid 32147810)
12. Tonin P, Weber B, Offit K et al (1996) Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 2:1179-1183